Order ID :	123456
Clinical ID :	ABC123
Indication :	Acute Myeloid Leukemia (AML) - NOS
Physician :	Dr. Smith
Patient Age :	65
Patient Gender :	Male
Patient Status :	Newly Diagnosed
Biopsy Date :	Nov 01, 2021
Sample Type :	Bone Marrow
Genomic Input :	NGS Report
Additional Input :	NA

The Cellworks proprietary workflow solution used to generate this test report from patient\'s medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. Cellworks reports have not been validated or specifically developed for pregnant women or nursing mothers. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software. Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice.

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

1. Drug Response Prediction

See the rationales in Section 6 for actionable molecular target and pathway.

Therapies of Interest	Patient Predicted Response
Azacitidine	Favorable Outcome
Azacitidine + Sorafenib	Favorable Outcome
Azacitidine + Venetoclax	Favorable Outcome
Cladribine + Cytarabine	Favorable Outcome
Cladribine + Cytarabine + Idarubicin	Favorable Outcome
Cladribine + Cytarabine + Mitoxantrone	Favorable Outcome
Clofarabine	Favorable Outcome
Clofarabine + Idarubicin	Favorable Outcome
Cytarabine	Favorable Outcome
Cytarabine + Daunorubicin	Favorable Outcome
Cytarabine + Daunorubicin + Etoposide	Favorable Outcome
Cytarabine + Daunorubicin + Gemtuzumab-ozogamicin	Favorable Outcome
Cytarabine + Daunorubicin + Midostaurin	Favorable Outcome
Cytarabine + Dexamethasone	Favorable Outcome
Cytarabine + Etoposide	Favorable Outcome
Cytarabine + Etoposide + Idarubicin	Favorable Outcome
Cytarabine + Etoposide + Mitoxantrone	Favorable Outcome
Cytarabine + Fludarabine	Favorable Outcome
Cytarabine + Fludarabine + Idarubicin	Favorable Outcome
Cytarabine + Gemtuzumab-ozogamicin	Favorable Outcome
Cytarabine + Glasdegib	Favorable Outcome
Cytarabine + Idarubicin	Favorable Outcome
Cytarabine + Midostaurin	Favorable Outcome
Cytarabine + Mitoxantrone	Favorable Outcome
Cytarabine + Venetoclax	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Therapies of Interest	Patient Predicted Response
Decitabine	Favorable Outcome
Decitabine + Sorafenib	Favorable Outcome
Decitabine + Venetoclax	Favorable Outcome
Gemtuzumab-ozogamicin	Favorable Outcome
Enasidenib	Non-Favorable Outcome
Gilteritinib	Non-Favorable Outcome
Hydroxyurea	Non-Favorable Outcome
Ivosidenib	Non-Favorable Outcome
Thioguanine	Non-Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

2. Master Regulators

The master regulators are uniquely selected for each patient. The Biosimulation process uses the master regulators to identify the targetable pathways for maximum phenotype impact. Up to 10 master regulators are shown her. See Section 7 for detailed illustrations of Specific Master Regulators and their impact on the patient's disease profile.

2.1 Master Regulator Impact Weight



Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

2.2 Treatment Impact on Master Regulators

The marks indicate whether each treatment has a meaningful impact on each of the master regulators. It is not required for each responder treatment to impact every master regulator since phenotype response can be driven by more than one pathway. Typically however, treatments that successful impact several master regulators tend to have the best outcomes.

Therapies of Interest	Master Regulators									
	CDKN1A	H2AFX	PARP1	FOXO3	ROCK1	NFKB1	E2F1	AURKB	GLI1	CEBPA
Azacitidine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Azacitidine + Sorafenib	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Azacitidine + Venetoclax	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cladribine + Cytarabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cladribine + Cytarabine + Idarubicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cladribine + Cytarabine + Mitoxantrone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Clofarabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Clofarabine + Idarubicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Daunorubicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Daunorubicin + Etoposide	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Daunorubicin + Gemtuzumab-ozogamicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Daunorubicin + Midostaurin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Dexamethasone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Etoposide	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Therapies of Interest	Patient Biomarker Characteristics									
	CDKN1A	H2AFX	PARP1	FOXO3	ROCK1	NFKB1	E2F1	AURKB	GLI1	CEBPA
Cytarabine + Etoposide + Idarubicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Etoposide + Mitoxantrone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Fludarabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Fludarabine + Idarubicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Gemtuzumab-ozogamicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Glasdegib	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Idarubicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Midostaurin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Mitoxantrone	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Cytarabine + Venetoclax	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Decitabine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Decitabine + Sorafenib	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Decitabine + Venetoclax	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Gemtuzumab-ozogamicin	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Enasidenib	✓		✓	✓	✓				✓	✓

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Therapies of Interest	Patient Biomarker Characteristics									
	CDKN1A	H2AFX	PARP1	FOXO3	ROCK1	NFKB1	E2F1	AURKB	GLI1	CEBPA
Gilteritinib										
Hydroxyurea										
Ivosidenib										
Thioguanine	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

3. Phenotype Index Values



Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

4. Clinical Trials

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT03573024	Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia	University of Colorado, Denver	Azacitidine	Favorable Outcome
NCT04629443	Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia	Institut de Recherches Internationales Servier	Azacitidine	Favorable Outcome
NCT04150029	A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy	Novartis Pharmaceuticals	Azacitidine	Favorable Outcome
NCT04905407	SY-1425 Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML	Syros Pharmaceuticals	Azacitidine	Favorable Outcome
NCT04086264	IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia	ImmunoGen, Inc.	Azacitidine	Favorable Outcome
NCT04256317	A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML	Astex Pharmaceuticals, Inc.	Azacitidine	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT04518345	TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia	Bhavana Bhatnagar	Azacitidine	Favorable Outcome
NCT04755244	A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)	ALX Oncology Inc.	Azacitidine	Favorable Outcome
NCT03586609	Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia	M.D. Anderson Cancer Center	Azacitidine	Favorable Outcome
NCT02719574	Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation	Forma Therapeutics, Inc.	Azacitidine	Favorable Outcome
NCT03164057	A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia	St. Jude Children's Research Hospital	Azacitidine + Sorafenib	Favorable Outcome
NCT04128501	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting	M.D. Anderson Cancer Center	Azacitidine + Venetoclax	Favorable Outcome
NCT04062266	AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission	M.D. Anderson Cancer Center	Azacitidine + Venetoclax	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT04435691	Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia	M.D. Anderson Cancer Center	Azacitidine + Venetoclax	Favorable Outcome
NCT04278768	Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS	Curis, Inc.	Azacitidine + Venetoclax	Favorable Outcome
NCT03471260	Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies	M.D. Anderson Cancer Center	Azacitidine + Venetoclax	Favorable Outcome
NCT03862157	Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	M.D. Anderson Cancer Center	Azacitidine + Venetoclax	Favorable Outcome
NCT04146038	Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Rutgers, The State University of New Jersey	Azacitidine + Venetoclax	Favorable Outcome
NCT04801797	Venetoclax + Azacitidine vs. Induction Chemotherapy in AML	Massachusetts General Hospital	Azacitidine + Venetoclax	Favorable Outcome
NCT04748848	A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy	Celgene	Azacitidine + Venetoclax	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT03150004	Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia	Medical College of Wisconsin	Cladribine + Cytarabine	Favorable Outcome
NCT01515527	Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)	M.D. Anderson Cancer Center	Cladribine + Cytarabine	Favorable Outcome
NCT04195945	CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients	Fred Hutchinson Cancer Research Center	Cladribine + Cytarabine	Favorable Outcome
NCT04047641	Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center	Cladribine + Cytarabine	Favorable Outcome
NCT02115295	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	M.D. Anderson Cancer Center	Cladribine + Cytarabine	Favorable Outcome
NCT04002115	Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML	Milton S. Hershey Medical Center	Clofarabine	Favorable Outcome
NCT03096782	Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma	M.D. Anderson Cancer Center	Clofarabine	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT04644016	Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders	Memorial Sloan Kettering Cancer Center	Clofarabine	Favorable Outcome
NCT04914676	Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission	University of Florida	Cytarabine	Favorable Outcome
NCT04526288	CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease	Fred Hutchinson Cancer Research Center	Cytarabine	Favorable Outcome
NCT03836209	Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia	PrECOG, LLC.	Cytarabine	Favorable Outcome
NCT03634228	Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia	M.D. Anderson Cancer Center	Cytarabine	Favorable Outcome
NCT03793478	Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood	Daiichi Sankyo, Inc.	Cytarabine	Favorable Outcome
NCT04817241	Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients	National Cancer Institute (NCI)	Cytarabine	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT04128748	Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center	Cytarabine + Daunorubicin	Favorable Outcome
NCT04778397	Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia	Gilead Sciences	Cytarabine + Daunorubicin	Favorable Outcome
NCT02521493	Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome	Children's Oncology Group	Cytarabine + Daunorubicin	Favorable Outcome
NCT03591510	A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML	Novartis Pharmaceuticals	Cytarabine + Daunorubicin	Favorable Outcome
NCT04240002	A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)	Astellas Pharma Global Development, Inc.	Cytarabine + Fludarabine	Favorable Outcome
NCT04657081	Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)	Astex Pharmaceuticals, Inc.	Decitabine	Favorable Outcome
NCT03306264	Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML	Astex Pharmaceuticals, Inc.	Decitabine	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT04746235	Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia	M.D. Anderson Cancer Center	Decitabine	Favorable Outcome
NCT04055844	Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS	Masonic Cancer Center, University of Minnesota	Decitabine	Favorable Outcome
NCT03404193	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center	Decitabine	Favorable Outcome
NCT05010122	ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center	Decitabine	Favorable Outcome
NCT03661307	Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	M.D. Anderson Cancer Center	Decitabine	Favorable Outcome
NCT04774393	Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	M.D. Anderson Cancer Center	Decitabine	Favorable Outcome
NCT04282187	Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms	University of Washington	Decitabine	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT04188405	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia	M.D. Anderson Cancer Center	Decitabine	Favorable Outcome
NCT04730258	A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML	Treadwell Therapeutics, Inc	Decitabine	Favorable Outcome
NCT03737955	Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm	University of Washington	Gemtuzumab-ozogamicin	Favorable Outcome
NCT03374332	Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia	John L. Reagan	Gemtuzumab-ozogamicin	Favorable Outcome
NCT03839446	Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy	Konstantinos Lontos	Gemtuzumab-ozogamicin	Favorable Outcome
NCT04849910	Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML	Vor Biopharma	Gemtuzumab-ozogamicin	Favorable Outcome
NCT04293562	A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations	Children's Oncology Group	Cytarabine + Daunorubicin	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clinical Trial Id	Trial Title	Trial Sponser	Treatment	Cellworks Prediction
NCT03860844	Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia	Sanofi	Cytarabine + Daunorubicin	Favorable Outcome

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

5. Patient Profile

5.1 Summary of Patient Genomic Profile

The table below includes all of the patient genomic and lab results used as input when generating this report.

Input Data Type	Mutations and CNV
Genetic Mutation(s)	29
Copy Number Variation(s)	407
Gene(s) Methylated	0

5.2 Detailed Information of Genomic Aberration(s) Modeled

The table below lists all of the gene mutations and copy number variations in chromosomal order.

5.2.1 Gene Mutation(s) with Gain of Function

ESRRA R377_A378delinsP	MUC4 A4166_D4213del
MUC4 S3736_A3737insSSTGQATPLPVTSTSSVSTGHVTPLHVTSPSS	MUC4 T3823_T3854del
MUC4 V3305_S3320del	PSPH G90S

5.2.2 Gene Mutation(s) with Loss of Function

ACO2 G463W	CDK12 D235del
CLSPN G328R	CMA1 splice_donor_variant
DDX3X splice_acceptor_variant	DDX3X splice_acceptor_variant_NMD_transcript_variant
FANCD2 splice_donor_variant	GALE R169W
HLAB Q94Hfs*4	KIR2DL1 K176Sfs*8
KIR2DL1 V177Afs*72	LIN28A R192*
MKI67 splice_acceptor_variant	MUC4 D3261Hfs*16
MUC4 P3478Ffs*23	MUC4 S3477Nfs*783
PPARA T71Sfs*11	PSPH splice_donor_variant
SDHA L649Efs*4	TP53 L383*
TTK S108T	ZDHHC11 W98*

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

5.2.3 Gene Mutations(s) with Switch of Function

IDH2 R140Q

5.2.4 Gene(s) with Increase in Copy Number Variation [CNV]

ANGPT1	ANGPT2	ASAH1	ASH2L	ATP6V1H	BAALC	BAG4	BLK
CCAR2	CCNE2	CEBPD	CLU	CNOT7	COPS5	CSGALNACT1	CTSB
CYP7A1	DEPTOR	DERL1	DGAT1	DKK4	DLC1	DPYS	E2F5
EGR3	EIF3E	EIF3H	EIF4EBP1	ELP3	EPHX2	ESRP1	EXT1
EYA1	FABP5	FBXO32	FBXO43	FDFT1	FGFR1	FNTA	GATA4
GFRA2	GGH	GPT	GSR	HAS2	HEY1	HSF1	IDO1
IDO2	IKBKB	IL7	KAT6A	KLF10	LOXL2	LPL	LY96
LYN	LYPLA1	MCM4	MIR30D	MMP16	MTDH	MTUS1	MYC
NAPRT	NBN	NCOA2	NDRG1	NEIL2	NRG1	NSD3	NSMAF
NUDT18	OPLAH	PAG1	PBK	PDLIM2	PDP1	PIP4P2	PLAT
POLB	PPP2R2A	PREX2	PRKDC	PTDSS1	PTK2	PTK2B	PTP4A3
RAB2A	RAD21	RAD54B	RB1CC1	RECQL4	RIPK2	RRM2B	RSPO2
RUNX1T1	SCRIB	SDC2	SFRP1	SFTPC	SGK3	SLC25A32	SNAI2
SOX17	SQLE	ST3GAL1	STK3	TCEA1	TERF1	TNFRSF10A	TNFRSF10B
TNFRSF10C	TNFRSF10D	TNFRSF11B	TNKS	TPD52	UBE2V2	UBR5	WRN
WWP1	XKR4	XKR9	YWHAZ	ZDHHC2	ZFPM2	ZNF703	

5.2.5 Gene(s) with Decrease in Copy Number Variation [CNV]

ABCB1	ABCB5	ACTB	ADA	ADCY1	ADCYAP1R1	ADRM1	AHR
AICDA	AKAP9	AKR1B10	ALG10	ANO6	ARID2	ARPC1A	ASB4
ASL	ASNS	ATG9B	AURKA	B4GALT5	BCL7B	BHLHA15	BHLHE41
BLVRA	BRAF	C1R	C1S	CAMK2B	CARD11	CASP2	CAV1
CCL26	CCND2	CD27	CD36	CD4	CD40	CDK5	CDK6
CDKN1B	CEBPB	CHD4	CHN2	CLDN4	CLEC2A	CLEC2B	CLEC2D

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

CLEC7A	CNOT4	COL1A2	COPS6	COPS7A	CREB3L2	CSE1L	CTCFL
CUL1	CUX1	CYCS	CYP24A1	CYP3A4	CYP51A1	DAGLB	DBF4
DDC	DGKB	DGKI	DMTF1	DNAJB6	DNAJB9	DOCK4	DPPA3
DUSP16	EGFR	EIF3B	ELMO1	ELMO2	ENO2	EPHA1	EPHB4
EPHB6	EPO	EPS8	ERC1	ETV1	ETV6	EXOC4	EZH2
FBXL13	FOXM1	FSCN1	FZD9	GABARAPL1	GAPDH	GGCT	GLI3
GNA12	GNAS	GRB10	GRIN2B	GSTK1	GTF2I	HBP1	HDAC9
HGF	HIPK2	HNF4A	HNRNPA2B1	HOXA1	HOXA10	HOXA11	HOXA13
HOXA2	HOXA3	HOXA5	HOXA7	HOXA9	HSPB1	HTR5A	HUS1
IGFBP1	IGFBP3	IKZF1	IL6	IMPDH1	ING4	INHBA	INSIG1
IRAK4	ITGB8	ITPR2	KDM5A	KDM7A	KLRB1	KLRC1	KLRC2
KLRF1	KLRF2	KLRG1	KLRG2	KLRK1	KMT2C	KMT2E	KRAS
L3MBTL1	LAG3	LAMA5	LAMB1	LDHB	LEP	LIMK1	LRP6
LRRK2	LTBR	MAD1L1	MAFK	MAGI2	MCM7	MDH2	MET
MGP	MGST1	MIOS	MIR182	MIR200C	MIR25	MIR29A	MIR29B1
MIR550A1	MLXIPL	MMP9	MNX1	MYBL2	NAMPT	NANOG	NCF1
NCOA3	NFATC2	NOS3	NRF1	NTF3	NUDT1	NUP205	OGDH
PAXIP1	PCK1	PDE3A	PDGFA	PDIA4	PDK4	PIK3CG	PMS2
PODXL	POLD2	POLM	POT1	PPP1R3A	PREX1	PRICKLE1	PRSS1
PSMA2	PSMA7	PSMC2	PSMG3	PTGIS	PTHLH	PTK6	PTN
PTPN1	PTPN6	PTPRO	PTPRT	PTPRZ1	RAC1	RAD52	RAE1
RALA	RASA4	RBM38	RFC2	RGS19	RHEB	RPA3	SALL4
SDC4	SEC61G	SEMA3A	SEMA3E	SERPINE1	SFRP4	SH2B2	SHH
SLC29A4	SLC2A3	SLC2A4RG	SLCO1A2	SLCO1B1	SLCO1B3	SLPI	SMO
SMURF1	SNAI1	SNX13	SPSB2	SRPK2	SRSF6	ST8SIA1	STEAP1
STEAP4	STK4	STX1A	TAPBPL	TAX1BP1	TBXAS1	TEAD4	TFPI2
TIGAR	TNFRSF1A	TPI1	TRIM24	TRRAP	TUBB1	TWIST1	UBE2C
UBE2V1	UBE3C	UPP1	USP42	USP5	VIPR2	WASL	WEE2

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

WIPI2	WNK1	XRCC2	YBX3	YWHAB	ZC3HC1	ZDHHC4	ZNF217

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

6. Therapy Rationale(s)

Rationales provided in this section highlight the pathways connected to drug sensitivity and resistance and include references to supporting published literature.

Species in red denote drug impact points. Species highlighted in blue are the Master Regulators.

Azacitidine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**AZACITIDINE** ⊣ **DNMT1** → **CPGMET** EZH2 → PRC2 COMPLEX → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	23671287 16357870 20601954 18360650

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Azacitidine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
IDH2	Switch of Function	Sensitive Pathway		19194470 28193779 33043739 25398940 12046058 12119358 21130701 23671287 12383256 22569363 25224413 26498513 10488096 19609947 26779436 11304577 18650261 28646232 21355845 28054552 22461507 24890832 17164422 24978161 21858223 23250430 12592393 16039586 12579297 19259613 26516376 23979523 21071137 15824892 26833217 19417127 24510345 16357870 12154409 29554906 22343901 25886188 24875481 24216483 11278353 24688109 9261115 14563837

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Azacitidine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
KAT6A	CNV Overexpression	Sensitive Pathway	**AZACITIDINE** ⊣ **DNMT1** → **CPGMET** KAT6A → EZH2 → PRC2_COMPLEX → CPGMET ⊣ CDKN1A ⊣ ROCK1 → CANCER PROGRESSION KAT6A → EZH2 → PRC2 COMPLEX → CPGMET ⊣ DUSP6 ⊣ MAPK3 → GLI1 → CANCER PROGRESSION KAT6A → EZH2 → PRC2_Complex → CPGMET ⊣ PPARG ⊣ NFKB1 → CANCER PROGRESSION KAT6A → EZH2 → PRC2 COMPLEX → CPGMET ⊣ CDKN1A ⊣ CDK2_CCNA2 → FOXM1 → CANCER PROGRESSION	23671287 25772242 16357870 18360650 16850502 7626805 18285455 12154409 12579297 18806826 28869966 15824892 24222120 19142899 26292171 15793220 30121333
GGH	CNV Overexpression	Resistant Pathway	**AZACITIDINE** ⊣ **DNMT1** → **CPGMET** GGH ⊣ S ADENOSYL METHIONINE → CPGMET ⊣ PPARG ⊣ NFKB1 → CANCER PROGRESSION	25886188 12154409 12383256 23671287 23647960 25502219 25224413
L3MBTL1	CNV Knockdown	Sensitive Pathway	**AZACITIDINE** ⊣ **DNMT1** → **CPGMET** L3MBTL1 ⊣ E2F1 → EZH2 → DNMT1 → CPGMET ⊣ CDKN1A ⊣ CDK2_CCNA2 → FOXM1 → CANCER PROGRESSION	7626805 16850502 18285455 11895758 17540172 23671287 16357870 21149733
PIK3CG	CNV Knockdown	Resistant Pathway	**AZACITIDINE** ⊣ **DNMT1** → **CPGMET** PIK3CG → PI45P2 → PTK2 ⊣ GSK3B ⊣ DNMT1 → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	17317726 27405758 12496760 32094334 15547111

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Cladribine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
HUS1	CNV Knockdown	Sensitive Pathway	**CLADRIBINE** → **2-CdATP** → **DNA DAMAGE** HUS1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	21242742 20188637 15314187 23361057
KMT2C	CNV Knockdown	Sensitive Pathway	**CLADRIBINE** → **2-CdATP** → **DNA DAMAGE** KMT2C → H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	21242742 24403070 15475387 24081332 25135975 25043185 23361057
MYC	CNV Overexpression	Resistant Pathway	**CLADRIBINE** → **2-CdATP** → **DNA DAMAGE** MYC → MYC_MAX → DHODH → dNTP ⊣ DCK → 2-CdAMP → 2-CdATP → DNA DAMAGE	21242742 27641501 18628958 3871794 25127121
PMS2	CNV Knockdown	Sensitive Pathway	**CLADRIBINE** → **2-CdATP** → **DNA DAMAGE** PMS2 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	21242742 23361057 11292842 19793570
RRM2B	CNV Overexpression	Resistant Pathway	**CLADRIBINE** → **2-CdATP** → **DNA DAMAGE** RRM2B → dNTP ⊣ DCK → 2-CdAMP → 2-CdATP → DNA DAMAGE	21242742 24024897 19842938 16918309
CLSPN	Loss of Function	Sensitive Pathway	**CLADRIBINE** → **2-CdA** → **2-CdAMP** → **2-CdADP** ⊣ **RRM1-RRM2** → **dNTP** ⊣ **REPLICATION STRESS** CLSPN → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	12766152 16126823 21242742 27625304
IDH2	Switch of Function	Sensitive Pathway	**CLADRIBINE** → **2-CdATP** → **DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	24403070 15475387 10072435 22395470 1707752 25886910 25398940

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Cladribine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**CLADRIBINE → 2-CdATP → DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ HOXA5 → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	21242742 26472914 16756717 15475387 10072435 25043185 22211105 24987060
KDM5A	CNV Knockdown	Resistant Pathway	**CLADRIBINE → 2-CdATP → DNA DAMAGE** KDM5A ⊣ H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	15475387 25043185 24403070 25190814 23361057 2311169
CUX1	CNV Knockdown	Sensitive Pathway	**CLADRIBINE → 2-CdA → 2-CdATP ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS** CUX1 → ATR → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	21242742 23056220 32316968 24038068 32187883 22319212

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clofarabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
PMS2	CNV Knockdown	Sensitive Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** PMS2 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	23663976 20544529 23361057 11292842 19793570
KMT2C	CNV Knockdown	Sensitive Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** KMT2C → H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	23663976 20544529 24403070 15475387 24081332 25135975 25043185 23361057
MYC	CNV Overexpression	Resistant Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** MYC → MYC_MAX → DHODH → dCTP ⊣ DCK → CAFdAMP → CAFdADP → CAFdATP → DNA DAMAGE	23663976 20544529 27641501 18628958 3871794 25127121
CLSPN	Loss of Function	Sensitive Pathway	**CLOFARABINE** → **CAFdADP** ⊣ **RRM1/2** → **dNTP** ⊣ **REPLICATION STRESS** CLSPN → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	19500427 20544529
RRM2B	CNV Overexpression	Resistant Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** RRM2B → dNTP ⊣ DCK → CAFdAMP → CAFdADP → CAFdATP → DNA DAMAGE	23663976 20544529 24024897 3484676 19842938 16918309
HUS1	CNV Knockdown	Sensitive Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** HUS1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	23663976 20544529 20188637 15314187 23361057
IDH2	Switch of Function	Sensitive Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	1707752 22395470 24403070 10072435 25886910 25398940 15475387

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Clofarabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ HOXA5 → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	23663976 20544529 26472914 16756717 15475387 10072435 25043185 22211105 24987060
KDM5A	CNV Knockdown	Resistant Pathway	**CLOFARABINE** → **CAFdATP** → **DNA DAMAGE** KDM5A ⊣ H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	15475387 2311169 25043185 25190814 24403070 23361057
CUX1	CNV Knockdown	Sensitive Pathway	**CLOFARABINE** → **CAFdADP** ⊣ **RRM1/2** → **dNTP** ⊣ **REPLICATION STRESS** CUX1 → ATR → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	21628579 28442502 32316968 24038068 32187883 22319212

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Cytarabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ HOXA5 → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	26472914 16756717 15475387 10072435 25043185 22211105 24987060 2311169
HUS1	CNV Knockdown	Sensitive Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** HUS1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	23361057 20188637 15314187 2311169
IDH2	Switch of Function	Sensitive Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	22395470 24403070 15475387 25886910 25398940 10072435 2311169
KDM5A	CNV Knockdown	Resistant Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** KDM5A ⊣ H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	15475387 24403070 25043185 23361057 2311169 25190814
KMT2C	CNV Knockdown	Sensitive Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** KMT2C → H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	24403070 15475387 24081332 25135975 25043185 23361057 2311169
MYC	CNV Overexpression	Resistant Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** MYC → MYC_MAX → DHODH → dCTP ⊣ DCK → AraCMP → AraCTP → DNA DAMAGE	27641501 3871794 18628958 25127121 2311169
PMS2	CNV Knockdown	Sensitive Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** PMS2 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	23361057 11292842 19793570 2311169

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Cytarabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
RRM2B	CNV Overexpression	Resistant Pathway	**CYTARABINE** → **AraCTP** → **DNA DAMAGE** RRM2B → dCTP ⊣ DCK → AraCMP → AraCTP → DNA DAMAGE	24024897 19842938 16918309 2311169
CLSPN	Loss of Function	Sensitive Pathway	**CYTARABINE** → **AraCTP** → **REPLICATION STRESS** CLSPN → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	16126823 12766152 27625304 2311169
CUX1	CNV Knockdown	Sensitive Pathway	**CYTARABINE** → **AraCTP** → **REPLICATION STRESS** CUX1 → ATR → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	22319212 28176818 22869869 29789314 27625304 25795119 2311169

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Daunorubicin				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
AKR1B10	CNV Knockdown	Sensitive Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** AKR1B10 ⊣ DAUNORUBICIN	21640744 9187272 2551497
IDH2	Switch of Function	Sensitive Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	25789047 25398940 12947386 6380596 23215809
MYC	CNV Overexpression	Resistant Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** MYC → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	2551497 11368379 20940401 17549079
EZH2	CNV Knockdown	Resistant Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	2551497 22211105 26472914 23388117 10964110
XRCC2	CNV Knockdown	Sensitive Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** XRCC2 → RAD51B → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	2551497 2049226 10517641 20189471 25418835 24130054
CDK5	CNV Knockdown	Sensitive Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** CDK5 → ATM → NBN → MRE11A-NBN-RAD50 → DNA REPAIR (HR) ⊣ DNA DAMAGE	2551497 19151707 25660209 19910469 27912094 23213480 10839544

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Daunorubicin				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
RAD52	CNV Knockdown	Sensitive Pathway	**DAUNORUBICIN** → **TOP2CC** → **DSB** → **DNA DAMAGE** RAD52 → DNA REPAIR (HR) ⊣ DNA DAMAGE	10667584 2049226

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Decitabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
IDH2	Switch of Function	Sensitive Pathway	**DECITABINE** ⊣ **DNMT1** → **CPGMET** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ PTPN6 ⊣ SRC → PIK3CA → AKT → CHUK_IKBKB → NFKB1 → CANCER PROGRESSION IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ CDKN1A ⊣ AP1 → CTNNB1 → CANCER PROGRESSION	21130701 23671287 12383256 22569363 25224413 25398940 15824892 24510345 26833217 29554906
KAT6A	CNV Overexpression	Sensitive Pathway	**DECITABINE** ⊣ **DNMT1** → **CPGMET** KAT6A → EZH2 → PRC2_COMPLEX → CPGMET ⊣ CDKN1A ⊣ ROCK1 → CANCER PROGRESSION KAT6A → EZH2 → PRC2 COMPLEX → CPGMET ⊣ DUSP6 ⊣ MAPK3 → GLI1 → CANCER PROGRESSION KAT6A → EZH2 → PRC2_COMPLEX → CPGMET ⊣ PPARG ⊣ NFKB1 → CANCER PROGRESSION KAT6A → EZH2 → PRC2 COMPLEX → CPGMET ⊣ CDKN1A ⊣ CDK2_CCNA2 → FOXM1 → CANCER PROGRESSION	23671287 25772242 16357870 18360650 16850502 7626805 18285455 20126405 25886188 12154409 23647960 12579297 18806826 28869966 15824892 24222120 19142899 26292171 15547111
EZH2	CNV Knockdown	Resistant Pathway	**DECITABINE** ⊣ **DNMT1** → **CPGMET** EZH2 → PRC2 COMPLEX → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	23671287 20126405 16357870 20601954 24688109 18360650
GGH	CNV Overexpression	Resistant Pathway	**DECITABINE** ⊣ **DNMT1** → **CPGMET** GGH ⊣ SAM → CPGMET ⊣ PPARG ⊣ NFKB1 → CANCER PROGRESSION	19417127 25502219 8647346 28122515
L3MBTL1	CNV Knockdown	Sensitive Pathway	**DECITABINE** ⊣ **DNMT1** → **CPGMET** L3MBTL1 ⊣ E2F1 → EZH2 → DNMT1 → CPGMET ⊣ CDKN1A ⊣ CDK2_CCNA2 → FOXM1 → CANCER PROGRESSION	7626805 16850502 20126405 18285455 11895758 17540172 16357870 21149733

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Decitabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
PIK3CG	CNV Knockdown	Resistant Pathway	**DECITABINE** ⊣ **DNMT1** → **CPGMET** PIK3CG → PI45P2 → PTK2 ⊣ GSK3B ⊣ DNMT1 → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	17317726 27405758 12496760 32094334 20126405

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Dexamethasone				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
CARD11	CNV Knockdown	Resistant Pathway	**DEXAMETHASONE** → **NR3C1** ⊣ **NFKB1** CARD11 → BCL10 → MALT1 → IKBKB → NFKB1 → CANCER PROGRESSION	22371499 10551779 25087226 12734399

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Enasidenib				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
IDH2	Switch of Function	Sensitive Pathway	**ENASIDENIB** ⊣ **IDH2** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ PPARG ⊣ NFKB1 → CANCER PROGRESSION	27073531 19417127 21130701 16025287 28588020 26516376 16830381
EZH2	CNV Knockdown	Resistant Pathway	**ENASIDENIB** ⊣ **IDH2** → **2-HG** ⊣ **TET2** ⊣ **CPGMET** EZH2 → PRC2 COMPLEX → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	28193778 28588019 16357870 32094334
PIK3CG	CNV Knockdown	Resistant Pathway	**ENASIDENIB** ⊣ **IDH2** → **2-HG** ⊣ **TET2** ⊣ **CPGMET** PIK3CG → PI45P2 → PTK2 ⊣ GSK3B ⊣ DNMT1 → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	17317726 27405758 12496760 32094334 20126405 28193778

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Etoposide				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	24766193 19377506 22211105 26472914 23388117 10964110
RAD52	CNV Knockdown	Sensitive Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** RAD52 → DNA REPAIR (HR) ⊣ DNA DAMAGE	24808172 29088754 16818498
IDH2	Switch of Function	Sensitive Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	11536045 21978880 2049226 21203981 25886910
XRCC2	CNV Knockdown	Sensitive Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** XRCC2 → RAD51B → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	24766193 19377506 10517641 20189471 25418835 24130054
CDK5	CNV Knockdown	Sensitive Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** CDK5 → ATM → NBN → MRE11A-NBN-RAD50 → DNA REPAIR (HR) ⊣ DNA DAMAGE	24766193 19377506 19151707 25660209 19910469 27912094 23213480 10839544
MYC	CNV Overexpression	Resistant Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** MYC → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	24766193 19377506 20940401 17549079
CDK12	Loss of Function	Sensitive Pathway	**ETOPOSIDE → TOP2CC → DSB → DNA DAMAGE** CDK12 → BRCA1 → DNA REPAIR(HR) ⊣ DNA DAMAGE	8910583 31615655

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Fludarabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
PMS2	CNV Knockdown	Sensitive Pathway	**FLUDARABINE → FaraATP → DNA DAMAGE** PMS2 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	7048062 3050447 23361057 11292842 19793570
KMT2C	CNV Knockdown	Sensitive Pathway	**FLUDARABINE → FaraATP → DNA DAMAGE** KMT2C → H3K4-TRIMETHYLATION → MSH6 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	7048062 3050447 24403070 15475387 24081332 25135975 25043185 23361057
HUS1	CNV Knockdown	Sensitive Pathway	**FLUDARABINE → FaraATP → DNA DAMAGE** HUS1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	7048062 3050447 20188637 15314187 23361057
MYC	CNV Overexpression	Resistant Pathway	**FLUDARABINE → FaraATP → DNA DAMAGE** MYC → MYC_MAX → DHODH → dCTP ⊣ DCK → FaraAMP → FaraADP → FaraATP → DNA DAMAGE	7048062 3050447 27641501 18628958 3871794 25127121
CLSPN	Loss of Function	Sensitive Pathway	**FLUDARABINE → FaraADP ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS** CLSPN → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	7048062 19500427
IDH2	Switch of Function	Sensitive Pathway	**FLUDARABINE → FaraATP → DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	25398940 15475387 22395470 7048062 25886910 10072435 24403070
RRM2B	CNV Overexpression	Resistant Pathway	**FLUDARABINE → FaraATP → DNA DAMAGE** RRM2B → dNTP ⊣ DCK → FaraAMP → FaraADP → FaraATP → DNA DAMAGE	7048062 3050447 24024897 3484676 19842938 16918309

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Fludarabine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**FLUDARABINE** → **FaraATP** → **DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ HOXA5 → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	7048062 3050447 26472914 16756717 15475387 10072435 25043185 22211105 24987060
KDM5A	CNV Knockdown	Resistant Pathway	**FLUDARABINE** → **FaraATP** → **DNA DAMAGE** KDM5A ⊣ H3K4 METHYLATION → MLH1 → DNA REPAIR (MMR) ⊣ DNA DAMAGE	15475387 25043185 24403070 25190814 23361057 2311169
CUX1	CNV Knockdown	Sensitive Pathway	**FLUDARABINE** → **FaraADP** ⊣ **RRM1/2** → **dNTP** ⊣ **REPLICATION STRESS** CUX1 → ATR → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	7048062 3050447 22319212 28176818 22869869 29789314 27625304 25795119

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Gemtuzumab-ozogamicin				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**GEMTUZUMAB-OZOGAMICIN** → **DSB** → **DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	28607471 22211105 26472914 23388117 10964110
FANCD2	Loss of Function	Sensitive Pathway	**GEMTUZUMAB-OZOGAMICIN** → **DSB** → **DNA DAMAGE** FANCD2 → FA COMPLEX → DNA REPAIR (HR) ⊣ DNA DAMAGE	28607471 26385482 24910428 15650050

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Glasdegib				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
SMO	CNV Knockdown	Resistant Pathway		25889765 22130798 28621241 19219074

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Hydroxyurea				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
HUS1	CNV Knockdown	Sensitive Pathway	**HYDROXYUREA ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS** HUS1 → RAD9A-HUS1-RAD1 → TOPBP1 → ATR → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	19576866 25091155 17575048
CLSPN	Loss of Function	Sensitive Pathway	**HYDROXYUREA ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS** CLSPN → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	19576866 19500427 12766152
RRM2B	CNV Overexpression	Resistant Pathway	**HYDROXYUREA ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS → APOPTOSIS** RRM2B → RRM1-RRM2B → dNTP ⊣ REPLICATION STRESS → APOPTOSIS	19576866 28416140 15221904
MYC	CNV Overexpression	Resistant Pathway	**HYDROXYUREA ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS → APOPTOSIS** MYC → dNTP ⊣ REPLICATION STRESS → APOPTOSIS	19576866 18677108 18628958 25869206
CDK5	CNV Knockdown	Sensitive Pathway	**HYDROXYUREA ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS** CDK5 → ATM → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	19576866 19151707 25660209 23508805
CUX1	CNV Knockdown	Sensitive Pathway	**HYDROXYUREA ⊣ RRM1/2 → dNTP ⊣ REPLICATION STRESS** CUX1 → ATR → CHEK1 ⊣ REPLICATION STRESS → APOPTOSIS	1641648 19015243 32316968 24038068 22319212

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Idarubicin				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	12034365 22211105 26472914 23388117 10964110
IDH2	Switch of Function	Sensitive Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	2049226 21913806 21130701 21203981 15546503 11536045 29367755 21870267
RAD52	CNV Knockdown	Sensitive Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** RAD52 → DNA REPAIR (HR) ⊣ DNA DAMAGE	10667584 2049226
AKR1B10	CNV Knockdown	Sensitive Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** AKR1B10 ⊣ IDARUBICIN	21640744 9187272 2551497
XRCC2	CNV Knockdown	Sensitive Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** XRCC2 → RAD51B → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	12034365 10517641 20189471 25418835 24130054
CDK5	CNV Knockdown	Sensitive Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** CDK5 → ATM → NBN → MRE11A-NBN-RAD50 → DNA REPAIR (HR) ⊣ DNA DAMAGE	12034365 19151707 25660209 19910469 27912094 23213480 10839544
MYC	CNV Overexpression	Resistant Pathway	**IDARUBICIN → TOP2CC → DSB → DNA DAMAGE** MYC → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	12034365 11368379 20940401 17549079

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Ivosidenib				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
EZH2	CNV Knockdown	Resistant Pathway	**IVOSIDENIB** ⊣ **IDH1** → **2-HG** ⊣ **TET2** ⊣ **CPGMET** EZH2 → PRC2 COMPLEX → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	30209701 16357870 32094334
PIK3CG	CNV Knockdown	Resistant Pathway	**IVOSIDENIB** ⊣ **IDH1** → **2-HG** ⊣ **TET2** ⊣ **CPGMET** PIK3CG → PI45P2 → PTK2 ⊣ GSK3B ⊣ DNMT1 → CPGMET ⊣ ZEB1 → CANCER PROGRESSION	17317726 27405758 12496760 32094334 20126405 30209701

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Midostaurin				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
PTPN6	CNV Knockdown	Resistant Pathway	**MIDOSTAURIN** ⊣ **FLT3** PTPN6 ⊣ CBL ⊣ FLT3	26416283 17446348 19654408

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Mitoxantrone				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
IDH2	Switch of Function	Sensitive Pathway	**MITOXANTRONE → TOP2CC → DSB → DNA DAMAGE** IDH2 → 2HG ⊣ TET2 ⊣ CPGMET ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	21913806 21130701 21203981 15546503 11536045 29367755 21870267
RAD52	CNV Knockdown	Sensitive Pathway	**MITOXANTRONE → TOP2CC → DSB → DNA DAMAGE** RAD52 → DNA REPAIR (HR) ⊣ DNA DAMAGE	10667584 14963025
XRCC2	CNV Knockdown	Sensitive Pathway	**MITOXANTRONE → TOP2CC → DSB → DNA DAMAGE** XRCC2 → RAD51B → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	14963025 10517641 20189471 25418835 24130054
CDK5	CNV Knockdown	Sensitive Pathway	**MITOXANTRONE → TOP2CC → DSB → DNA DAMAGE** CDK5 → ATM → NBN → MRE11A-NBN-RAD50 → DNA REPAIR (HR) ⊣ DNA DAMAGE	14963025 19151707 25660209 19910469 27912094 23213480 10839544
MYC	CNV Overexpression	Resistant Pathway	**MITOXANTRONE → TOP2CC → DSB → DNA DAMAGE** MYC → RAD51 → DNA REPAIR (HR) ⊣ DNA DAMAGE	14963025 20940401 17549079
EZH2	CNV Knockdown	Resistant Pathway	**MITOXANTRONE → TOP2CC → DSB → DNA DAMAGE** EZH2 → PRC2 COMPLEX → H3K27 METHYLATION ⊣ BRCA1/2 → DNA REPAIR (HR) ⊣ DNA DAMAGE	14963025 22211105 26472914 23388117 10964110

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Sorafenib				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
PTPRZ1	CNV Knockdown	Resistant Pathway	**SORAFENIB** ⊣ **RAF1** PTPRZ1 → PTEN ⊣ PI345P3 → PDPK1 → AKT ⊣ RAF1	16757355 10576742 31205522 21779440
PTPN6	CNV Knockdown	Resistant Pathway	**SORAFENIB** → **PTPN6** PTPN6 ⊣ STAT3 → MCL1 ⊣ BAX → APOPTOSIS	23908138 21718664 21354226 22871485
SDHA	Loss of Function	Sensitive Pathway	**SORAFENIB** ⊣ **KDR** SDHA ⊣ HIF1A → KDR → SRC → PIK3CA → AKT ⊣ GSK3B ⊣ MYC → GLI1 → CANCER PROGRESSION	16757355 16195397 8641834 12509223 21840963 11035810 14563837 23525267
FGFR1	CNV Overexpression	Resistant Pathway	**SORAFENIB** ⊣ **RAF1** → **MAP2K1/2** → **MAPK1/3** ⊣ **FRS2** FGFR1 → FRS2 → SRC → PIK3CA → PI345P3 → PDPK1 → AKT → CHUK_IKBKB → NFKB1 → CANCER PROGRESSION FGFR1 → FRS2 → SRC → PIK3CA → PI345P3 → PDPK1 → AKT ⊣ GSK3B ⊣ MYC → GLI1 → CANCER PROGRESSION	20460524 25900027 30514931 23525267 28712664 16757355 27342992 19609947

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Thioguanine				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
KMT2C	CNV Knockdown	Resistant Pathway	**THIOGUANINE** → **6TG** → **TdGTP** → **MMR** → **FUTILE REPAIR** → **DNA DAMAGE** KMT2C → H3K4 METHYLATION → MLH1 → MMR	29449434 12796402 13608442 20498393 24081332 25135975
PMS2	CNV Knockdown	Resistant Pathway	**THIOGUANINE** → **6TG** → **TdGTP** → **MMR** → **FUTILE REPAIR** → **DNA DAMAGE** PMS2 → MMR	20498393 12867608 10381918 12796402 29449434 19793570 13608442

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Venetoclax				
Gene	Status	Type	Gene Status Drug Action Pathway(s)	Supporting PMID(s)
RB1CC1	CNV Overexpression	Resistant Pathway	**VENETOCLAX** ⊣ **BCL2** ⊣ **BAX** → **APOPTOSIS** RB1CC1 → RB1 ⊣ E2F1 → BCL2L11 ⊣ MCL1 ⊣ BAX → APOPTOSIS (Upregulation of MCL1 leads to Venetoclax resistance)	23291630 25590803 20614030 26939706 23152504 29202480 27103402
MYC	CNV Overexpression	Resistant Pathway	**VENETOCLAX** ⊣ **BCL2** ⊣ **BAX** MYC → MCL1 ⊣ BAX → APOPTOSIS (Upregulation of MCL1 leads to Venetoclax resistance)	22456335 26939706 27252989
KAT6A	CNV Overexpression	Resistant Pathway	**VENETOCLAX** ⊣ **BCL2** KAT6A → EZH2 → PRC2 COMPLEX → H3K27 TRIMETHYLATION ⊣ BCL2	23291630
IDH2	Switch of Function	Sensitive Pathway	**VENETOCLAX** ⊣ **BCL2** IDH2 → 2HG → HIF1A → BCL2 → CANCER PROGRESSION	28386377 19935646 27520294 25599133 23291630 19359588
TP53	Loss of Function	Sensitive Pathway	**VENETOCLAX** ⊣ **BCL2** TP53 ⊣ BCL2 ⊣ BAX → APOPTOSIS	23291630 11313951 18178565 11073801

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

7. Genomic Aberration to Master Regulator Pathway(s)

This section provides a snapshot of paths connecting the most significant gene aberrations with patient master regulators and references to published research supporting these pathways.

RED: Gain of Function/Switch of Function Mutation(s) or Amplified Gene(s) BLUE: Loss of Function Mutation(s) or Deleted Gene(s)

TRANSCRIPTION FACTORS:

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
NFKB1	COPS5 → CUL4A → CUL4A_DDB1 ⊣ ULK1 → FBP1 ⊣ NPM1 → NFKB1	21258367
	ZNF703 → CUL4A_DDB1 ⊣ ULK1 → FBP1 ⊣ NPM1 → NFKB1	21258367
	TP53 ⊣ NFKB1	17567906
	HUS1 → HUS1_RAD1 → TOPBP1 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → PRDX1 → NFKB1	11395493 12773567 17575048 20029092 8428596
	MYC → PCNA → DNMT1 → CPGMET ⊣ CDKN1A ⊣ CCNB1_CDK1 → PRDX1 → NFKB1	12145218 12408820 12711675 15616584 16474839 17576694 9989826
	PRKDC → AKT ⊣ CHEK1 → WEE1 ⊣ CCNB1_CDK1 → PRDX1 → NFKB1	12517798 15710331 23748345 8428596
	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → PRDX1 → NFKB1	8428596
NFKB1	IKBKB → NFKB1	10356400 10747026 17298882 18571841
	RIPK2 → BCL10 → MALT1 → PRKCE → AKT ⊣ CHEK1 → WEE1 ⊣ CCNB1_CDK1 → PRDX1 → NFKB1	12517798 14638696 15125833 15710331 20516126 23690623 23748345 8428596

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
E2F1	EIF3H → EIF3E → CUL3_KLHL18 → AURKA → E2F1	20300951 23213400
	ZNF703 → CUL4A_DDB1 ⊣ ULK1 → FBP1 ⊣ NPM1 → AURKA → E2F1	20300951 21258367 9418871
	ESRP1 → FGFR2 → PTPN11 → KRAS → TIAM1 → RAC1 → PAK1 → AURKA → E2F1	11438654 14988728 20300951 22247021
	TP53 → PRKAA1 → ULK1 → FBP1 ⊣ NPM1 → AURKA → E2F1	12198151 14627987 17409411 19610065 20300951
	LYN → DOCK1 → CDC42 → PAK1 → AURKA → E2F1	19182796 20300951 22323579
	MYC → PCNA → DNMT1 ⊣ FBP1 ⊣ NPM1 → AURKA → E2F1	17576694 20300951
	PTP4A3 → ITGA1_ITGB1 → ILK → PTK2 → DNM2 → RAC1 → PAK1 → AURKA → E2F1	12782622 15673687 19118217 19889638 20300951 21102636 21474670 25501815 8538749 8649427 9736715
	CTSB → PLAU → PLAUR → PTPN11 → KRAS → TIAM1 → RAC1 → PAK1 → AURKA → E2F1	11438654 14988728 15677342 1900515 19133257 20300951 22247021
	EIF3E → CUL3_KLHL18 → AURKA → E2F1	20300951 23213400
	PRKDC → AKT ⊣ STK11 → PRKAA1 → ULK1 → FBP1 ⊣ NPM1 → AURKA → E2F1	14985505 15231735 16027121 20300951 20412774 21159649 22611470 23518498
E2F1	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → CDK1 → DNM2 → RAC1 → PAK1 → AURKA → E2F1	20300951 8428596

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
CEBPA	FNTA → NRAS → RAF1 → XIAP → AKT → DNMT1 ⊣ CEBPA	16964381 21151116 23640046
	YWHAZ → RAF1 → XIAP → AKT → DNMT1 ⊣ CEBPA	16964381 21151116 23640046
	ZNF703 → CUL4A_DDB1 → GRB10 → AKT → DNMT1 ⊣ CEBPA	15718470 16221682 16226444 19995915 21151116 21659605
	ESRP1 → FGFR2 → PLCG1 → PRKCE → AKT → DNMT1 ⊣ CEBPA	21151116
	LYN → PLCG2 → PRKCE → AKT → DNMT1 ⊣ CEBPA	21151116 8395016
	MYC → PCNA → DNMT1 ⊣ CEBPA	17576694
	PTP4A3 → ITGA1_ITGB1 → FLT4 → PIK3CA → PDPK1 → AKT → DNMT1 ⊣ CEBPA	10698680 11553610 21151116 8662748
	PTPN6 ⊣ PIK3CA → PDPK1 → AKT → DNMT1 ⊣ CEBPA	10698680 11406619 12105209 12616480 12874320 18064631 19289601 21151116
	PRKDC → AKT → DNMT1 ⊣ CEBPA	21151116
	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → XIAP → AKT → DNMT1 ⊣ CEBPA	17991895 21151116 23640046 27927753 8428596
CEBPA	RIPK2 → BCL10 → MALT1 → PRKCE → AKT → DNMT1 ⊣ CEBPA	14638696 15125833 20516126 21151116 23690623
	STK4 → LATS1 ⊣ YAP1 → BIRC5 → AKT → DNMT1 ⊣ CEBPA	15688006 17379520 19962312 21151116 21199877 23245941 27847303

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
FOXO3	FNTA → NRAS → RAF1 → XIAP → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 16027121 16964381 20412774 21159649 22611470 23640046
	YWHAZ → RAF1 → XIAP → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 16027121 16964381 20412774 21159649 22611470 23640046
	ZNF703 → CUL4A_DDB1 → GRB10 → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 15718470 16027121 16221682 16226444 18692468 19995915 20412774 21159649 21460630 21659605
	ESRP1 → FGFR2 → PLCG1 → PRKCE → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 16027121 20412774 21159649 22611470
	TP53 → PRKAA1 → SIRT2 → FOXO3	17409411
	LYN → PLCG2 → PRKCE → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 16027121 20412774 21159649 22611470 8395016
	PTP4A3 → ITGA1_ITGB1 → FLT4 → PIK3CA → PDPK1 → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	10698680 11553610 14985505 15231735 16027121 20412774 21159649 21775285 22611470 8662748
	PTPN6 ⊣ PIK3CA → PDPK1 → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	10698680 11406619 12105209 12616480 12874320 14985505 15125833 15231735 16027121 18064631 19289601 20412774
	CDK12 → BRCA1 → CDKN1A ⊣ CSNK2A1 → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	11255227 14985505 15231735 16027121 20412774 21159649 22611470
	PRKDC → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 16027121 20412774 21159649 22611470

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
FOXO3	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → XIAP → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 16027121 20412774 21159649 22611470 23640046 27927753 8428596
	RIPK2 → BCL10 → MALT1 → PRKCE → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14638696 14985505 15125833 15231735 16027121 20412774 20516126 21159649 22611470 23690623
	STK4 → LATS1 ⊣ YAP1 → BIRC5 → AKT ⊣ STK11 → PRKAA1 → SIRT2 → FOXO3	14985505 15231735 15688006 16027121 17379520 19962312 20412774 21159649 21199877 22611470 23245941 27847303

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
GLI1	FNTA → NRAS → RAF1 → PLK1 → NEK2 → GLI1	
	YWHAZ → RAF1 → PLK1 → NEK2 → GLI1	
	EIF3H → EIF3E → CUL3_KLHL18 → AURKA → PLK1 → NEK2 → GLI1	23213400
	ZNF703 → CUL4A_DDB1 → EED → CPGMET ⊣ BRCA1 ⊣ PLK1 → NEK2 → GLI1	16357870 17041588 24067368
	ESRP1 → FGFR2 → PTPN11 → KRAS → RAF1 → PLK1 → NEK2 → GLI1	
	TP53 ⊣ BCL2 ⊣ BRCA1 ⊣ PLK1 → NEK2 → GLI1	10406804 17567906 17823980 19128456 21444675 22295238 24067368 8898082
	HUS1 → HUS1_RAD1 → TOPBP1 → ATRIP → BRCA1 ⊣ PLK1 → NEK2 → GLI1	11395493 12773567 16530042 17575048 20029092 23582259 24067368
	LYN → CSF3R_LYN → PTPN11 → KRAS → RAF1 → PLK1 → NEK2 → GLI1	9824671
	MYC → PCNA → DNMT1 ⊣ BRCA1 ⊣ PLK1 → NEK2 → GLI1	17576694 24067368 24771642 24944674
	WIPI2 → MAP1LC3B ⊣ TRAF6 → PIK3CA → PDPK1 → RPS6KA3 → NEK2 → GLI1	11406619 11923207 12105209 12616480 12874320 18064631 19289601 9445476

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Master Regulator(s)	Molecular Pathway Rationale for Master Regulator(s)	Reference PMID(s)
GLI1	PTP4A3 → ITGA1_ITGB1 → FLT4 → PIK3CA → PDPK1 → RPS6KA3 → NEK2 → GLI1	11553610 11923207 8662748 9445476
	PTPN6 ⊣ PIK3CA → PDPK1 → RPS6KA3 → NEK2 → GLI1	11406619 11923207 12105209 12616480 12874320 18064631 19289601 9445476
	CDK12 → BRCA1 ⊣ PLK1 → NEK2 → GLI1	24067368
	CTSB → PLAU → PLAUR → PTPN11 → KRAS → RAF1 → PLK1 → NEK2 → GLI1	15677342 1900515 19133257
	EIF3E → CUL3_KLHL18 → AURKA → PLK1 → NEK2 → GLI1	23213400
	PRKDC → AKT ⊣ BAD ⊣ BCL2 ⊣ BRCA1 ⊣ PLK1 → NEK2 → GLI1	10880354 11050396 11707444 12897128 14641020 15694340 15990872 16873482 17322918 18951090 19667065 21444675
	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → BORA → PLK1 → NEK2 → GLI1	18566290 24067368 8428596

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

KINASE**:

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
AURKB	FNTA → NRAS → RALGDS → RALA → CCNB1_CDK1 → BIRC5 → AURKB	11322487 15208305 19158485 20118982 20200357
	YWHAZ → RAF1 → PLK1 → CDC25C → CCNB1_CDK1 → BIRC5 → AURKB	19158485
	EIF3H → EIF3E → CUL3_KLHL18 → AURKA → RALA → CCNB1_CDK1 → BIRC5 → AURKB	15208305 19158485 23213400
	ESRP1 → FGFR2 → PTPN11 → KRAS → RALGDS → RALA → CCNB1_CDK1 → BIRC5 → AURKB	11322487 15208305 19158485
	TP53 ⊣ BIRC5 → AURKB	16595680 18027854 21920899
	HUS1 → HUS1_RAD1 → TOPBP1 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → BIRC5 → AURKB	11395493 12773567 17575048 19158485 20029092 8428596
	LYN → CSF3R_LYN → PTPN11 → KRAS → RALGDS → RALA → CCNB1_CDK1 → BIRC5 → AURKB	11322487 15208305 19158485 9824671
	MYC → PCNA → DNMT1 → CPGMET ⊣ CDKN1A ⊣ CCNB1_CDK1 → BIRC5 → AURKB	12145218 12408820 12711675 15616584 16474839 17576694 19158485 9989826
	PTP4A3 → ITGA1_ITGB1 → FLT4 → PIK3CA → PDPK1 → AKT ⊣ STK11 ⊣ YAP1 → BIRC5 → AURKB	10698680 11553610 12535517 22611470 23027127 23245941 8662748
	PTPN6 ⊣ PIK3CA → PDPK1 → AKT ⊣ STK11 ⊣ YAP1 → BIRC5 → AURKB	10698680 11406619 12105209 12535517 12616480 12874320 18064631 19289601 22611470 23027127 23245941

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
AURKB	CTSB → PLAU → PLAUR → PTPN11 → KRAS → RALGDS → RALA → CCNB1_CDK1 → BIRC5 → AURKB	11322487 15208305 15677342 1900515 19133257 19158485
	EIF3E → CUL3_KLHL18 → AURKA → RALA → CCNB1_CDK1 → BIRC5 → AURKB	15208305 19158485 23213400
	PRKDC → AKT ⊣ STK11 ⊣ YAP1 → BIRC5 → AURKB	12535517 22611470 23027127 23245941
	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → BIRC5 → AURKB	19158485 8428596
	RIPK2 → BCL10 → MALT1 → PRKCE → AKT ⊣ STK11 ⊣ YAP1 → BIRC5 → AURKB	12535517 14638696 15125833 20516126 22611470 23027127 23245941 23690623
	STK4 → LATS1 ⊣ YAP1 → BIRC5 → AURKB	15688006 17379520 19962312 21199877 23245941 27847303

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
ROCK1	FNTA → NRAS → RAF1 → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 16964381
	YWHAZ → RAF1 → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 16964381
	EIF3H → EIF3E → CUL3_KLHL18 → AURKA → PTK2 → DNM2 → RAC1 → RHOA → ROCK1	12782622 16187236 23213400 25501815
	ZNF703 → CUL4A_DDB1 → GRB10 → AKT → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 14645242 15718470 16221682 16226444 19995915 21659605 22984590 8810315
	ESRP1 → FGFR2 → PLCG1 → PRKCE → RHOA → ROCK1	
	TP53 ⊣ PTK2 → DNM2 → RAC1 → RHOA → ROCK1	12782622 15157737 16187236 17725966
	LYN → PTK2 → DNM2 → RAC1 → RHOA → ROCK1	12782622 16187236
	MYC → PCNA → DNMT1 → CPGMET ⊣ CDKN1A ⊣ CCNB1_CDK1 → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 12145218 12408820 12711675 15616584 16474839 17576694 27927753 9989826
	PTP4A3 → ITGA1_ITGB1 → ILK → PTK2 → DNM2 → RAC1 → RHOA → ROCK1	12782622 16187236 19118217 19889638 21102636 8538749 8649427 9736715
	PTPN6 ⊣ BTK → PLCG2 → PRKCE → RHOA → ROCK1	11507089 11788586 12093870 12724322 15184383 23836557 8691147

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

Key Biomarker(s)	Molecular Pathway Rationale for Biomarker(s)	Reference PMID(s)
ROCK1	CTSB → PLAU → PLAUR → PTPN11 → KRAS → TIAM1 → RAC1 → RHOA → ROCK1	10893266 14988728 15677342 1900515 19133257 22247021
	EIF3E → CUL3_KLHL18 → AURKA → PTK2 → DNM2 → RAC1 → RHOA → ROCK1	12782622 16187236 23213400 25501815
	PRKDC → AKT → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 14645242 22984590 23640046 8810315
	PMS2 → CHEK1 → WEE1 ⊣ CCNB1_CDK1 → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 27927753 8428596
	RIPK2 → BCL10 → MALT1 → PRKCE → RHOA → ROCK1	14638696 15125833 20516126 23690623
	STK4 → LATS1 ⊣ YAP1 → BIRC5 → AKT → XIAP → TGFBR1_TGFBR2 → RHOA → ROCK1	11356828 14645242 15688006 17379520 19962312 21199877 22984590 23245941 23640046 27847303 8810315

** Assayable key kinase biomarkers identified for this patient.

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

8. Singula™ Assessment sections: How to Read the Report

Cellworks Precision Medicine Reports equip oncologists with the knowledge of how an individual patient will respond to all standard care drugs (Singula™) and novel combination therapies (Ventura™) prior to treatment. The biosimulation analyzes mutational interactions of 4,000+ networked genes to predict and rank phenotype responses to millions of drug combinations.

Singula™ reports predict an individual patent's response to Standard Care therapies.

Please Note:

The current assessment assumes that the drugs are faithfully delivered to the site of action. Cellworks considers all molecular interactions once the therapy is delivered to the site of action (Pharmacodynamics of the drug compound). Cellworks does not account for absorption, distribution, metabolism & excretion (ADME) properties of the drug that determine how the drug is delivered to the site of action. Any toxicity in the delivery process, or pharmacokinetics, is not considered.

Cellworks does not provide recommendations on drug dosage. However, it is highly recommended to follow the dosage instructions in the drug FDA labels and standard guidelines.

1. Drug Response Prediction

The 'Therapies of Interest' column lists the Standard Care drugs for a given indication. Cellworks digital drug models of these therapies are biosimulated on the patient disease model. The predicted outcome of treatment with each of these drugs is printed in the 'Patient Predicted Response' column. An entry of 'Responder' indicates that the patient is predicted to respond to the corresponding drug. This means the drug has impacted the master regulators and disease phenotypes to a significant extent; an entry of 'Non-Responder' indicates that the patient is predicted to not respond to the corresponding drug implying that the drug did not sufficiently impact the patient specific master regulators and disease phenotypes.

A detailed rationale explaining each predicted treatment outcome is provided in the 'Therapy Rationale' section (Section 5).

2. Patient Specific Master Regulators

Cellworks multi-omics biosimulation determines master regulators in the patient's disease network. They are points of convergence of the pathways impacted by the aberrations in the patient's genomic profile. These master regulators are tumor promoter/suppressor genes that a drug needs to impact for the patient to respond to treatment.

Detailed illustrations showing molecular biochemical pathways from genomic aberrations in the patient profile to the master regulators are provided in the Genomic Aberration to Master Regulator Pathway Section (Section 6).

3. Treatment Impact on Master Regulators

Cellworks multi-omics biosimulation classifies a patient as a responder or a non-responder to a drug based on the impact the drug has on the phenotype of the patient's cancer as well as the impact on the master regulators identified in the patient's disease network.

If the drug successfully impacts a master regulator to a significant extent, it is represented by a check symbol ('✓'). Absence of a check symbol

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

implies that the drug does not sufficiently impact the master regulator.

4.1 Summary of Patient Genomic Profile

This section provides a summary of the patient genomics used for therapy assessment. It shows the type of input received from the next generation sequencing data (NGS) with the number of genetic mutations, copy number variations (CNVs) and any epigenetic data that is reported. Some indications also require additional lab tests as input to the biosimulation process.

4.2 Aberrations by Chromosome Location

The plot contains the CNVs from the patient profile as determined by NGS, showing gain and loss values. The values are plotted in chromosomal order for ease of understanding. The genomic mutations are plotted at the bottom of the chart colored to illustrate gain of function (blue dot), loss of function (red dot), or switch of function (purple dot).

4.3 Detailed Information of Genomic Aberration(s) Modeled

Aberrations of oncogenic significance found in the patient's genomic profile are used to create the disease model of the patient and are listed in this section. Based on the type of mutation and original functionality of a gene, aberrations are categorized into 5 major groups -

I. Gene Mutation(s) with Gain of Function
II. Gene Mutation(s) with Loss of Function
III. Gene Mutation(s) with Switch of Function
IV. Gene(s) with Increase in Copy Number Variation [CNV]
V. Gene(s) with Decrease in Copy Number Variation [CNV]

This information forms the patient-specific input on which a Cellworks assessment is based.

5. Therapy Rationales

Each therapy recommendation made in a Cellworks report is accompanied by a clear rationale explaining the reason behind the recommendation.

A therapy rationale illustrates the role of key aberrations in causing sensitivity or resistance to drugs. A drug will have a therapy rationale for every aberration that contributes significantly to its sensitivity or resistance.

The first illustration in the rationale defines the mechanism of action of the drug.

The second illustration articulates the signaling or metabolic pathway by which the aberration of interest contributes to drug sensitivity or resistance including the point of intersection with the drug's mechanism of action.

The pathway can be read as a dependent relationship (represented by an arrow) where an increase in one gene increases the next, or a block or inverse relationship (represented by a line with a bar) where an increase in one gene decreases the next. The description is accompanied by relevant PMID references that support the drug mechanism of action and rationale for drug sensitivity or resistance.

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

6. Genomic Aberration to Key Biomarker Pathway(s)

This section illustrates molecular biochemical pathways from a genomic aberration in the patient profile to critical master regulators identified by Cellworks' multi-omics biosimulation. These illustrations explain why the master regulators listed in Section 2 are important to the patient's disease network. The illustration is accompanied by relevant PMID references that were used to determine the interaction.

Acute Myeloid Leukemia (AML) - NOS

Clinical ID: ABC123 **Cellworks ID:** 123456 **Ref Physician:** Dr. Smith

9. Terms of Use:

Cellworks Therapeutic Solutions

The Cellworks proprietary workflow solution used to generate this test report from patient's medical records (Test Report), has not been approved by any regulatory or medical authority. Cellworks generated information is adjunctive information to physicians and molecular tumor boards. CELLWORKS DOES NOT ASSURE OR GUARANTEE THE SUCCESS OF ANY THERAPEUTIC OPTION IDENTIFIED IN THIS TEST REPORT. Cellworks reports have not been validated or specifically developed for pregnant women or nursing mothers. The therapeutic options provided in the Test Report are not ranked in order of efficacy, safety or cost-effectiveness and are sorted based on our model's analysis of the input data. All individual drugs included in therapy options identified in the Test Report have been cleared and approved by the United States Food and Drug Administration (FDA) for other indications. At the specific request of the patient or treating physician, the Test Report may identify drugs or therapy options that are also in an advanced stage of clinical trials and yet to be approved. This will provide adjunctive information to the physicians for selecting a clinical trial for the patient.

Therapeutic agents associated with potential benefit or lack of benefit, as indicated in the Test Report are based on biomarker results provided in the report and on published evidence with PMID references. This evidence in some cases may have been obtained from studies performed in the cancer type present in the tested patient's sample.

No Guarantee of Clinical Benefit

The finding of a biomarker expression does not necessarily indicate pharmacologic effectiveness or lack thereof. The agents identified may or may not be suitable for use with a particular patient and the Test Report does not guarantee or suggest that any particular agent will be effective with the treatment of any particular condition. The user of this Test Report remains responsible for the conduct of patient care and for evaluating the clinical relevance of information provided by the prediction software.

Intended Use

Cellworks is not an entity licensed to practice medicine or clinical activity and the Test Report generated by Cellworks does not amount to, or substitute, qualified professional medical advice. THIS REPORT IS PREPARED AS ADJUNCTIVE INFORMATION TO ASSIST HEALTH CARE PROVIDERS TO EVALUATE THEIR PATIENTS. CELLWORKS IS NOT RESPONSIBLE FOR ANY USE OF THIS TEST REPORT OR DATA BY ANY UNQUALIFIED PERSON. Decisions on patient care and treatment, including safety and security of treatments based on this Test Report must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition and the treatment should not solely be based on this Test Report. Cellworks provides no guarantee of the accuracy, relevance, exhaustiveness or appropriateness of any of the medical information referenced through this Test Report.

CELLWORKS DISCLAIMS ALL WARRANTIES, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF TITLE, NON- INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IN RELATION TO INTERFACE, ITS SERVICES AND THE TEST REPORT. CELLWORKS PROVIDES NO ASSURANCE OR GUARANTEE THAT A HEALTHCARE PROVIDER, INSURER OR ANY OTHER THIRD PARTY PAYOR, WHETHER GOVERNMENTAL OR PRIVATE, WILL REIMBURSE A PATIENT FOR THE COST OF GENERATING TEST REPORT.

This is an automatically generated report. No signature is required.
--END OF THE REPORT--